The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Ustekinumab Can Be Used to Safely Treat Teens & More

Ustekinumab Can Be Used to Safely Treat Teens & More

October 7, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Treating Teenagers with Ustekinumab
The results of a Phase 3 study treating adolescents with ustekinumab for moderate to severe psoriasis were recently published. In this study, patients (n=110) age 12–17 years old were randomized to receive ustekinumab or a placebo.1

You Might Also Like
  • Ustekinumab Found to Be Effective in Adolescents with Psoriasis
  • FDA Approves Ustekinumab for Crohn’s Disease
  • Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis
Also By This Author
  • Tofacitinib Promising for Adults with AS

Ustekinumab doses were 0.75 mg/kg (the standard dosage for patients weighing less than 60 kg), 45 mg fixed (for patients weighing greater than 60 kg, but less than or equal to 100 kg) and 90 mg fixed (for patients weighing more than 100 kg). A half-standard dose was also used: 0.375 mg/kg for patients weighing less than 60 kg; 22.5 mg for patients weighing greater than 60 kg, but less than or equal to 100 kg; or 45 mg for patients weighing more than 100 kg. Patients received ustekinumab at Weeks 0, 4 and every 12 weeks; or placebo at Weeks 0 and 4 with crossover to ustekinumab (standard or half dose) at Week 12.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Clinical assessments included the proportion of patients achieving a Physician’s Global Assessment of cleared/minimal (PGA 0/1), at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) and at least 90% in PASI (PASI 90). Adverse events were monitored through Week 60.

Baseline demographics were similar across treatment groups. The mean age was 15.2 years, with most patients being 15–17 years old (n=77). Mean body weight was 65 kg, with 51 patients (46%) weighing ≤60 kg, 56 (51%) weighing >60 kg but ≤100 kg, and three patients (3%) weighing >100 kg.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At Week 12, 68% and 69% of patients receiving ustekinumab half and standard dose, respectively, achieved PGA 0/1, compared with 5% (P <0.001) of placebo-treated patients. Significantly greater proportions of ustekinumab-treated patients achieved PASI 75 (half-standard dose, 78%; standard dose, 81%; placebo, 11%) or PASI 90 (half-standard dose, 54%; standard dose, 61%; placebo, 5%) at Week 12 (P<0.001).

The rates of adverse events were similar across the groups. The most common adverse events were nasopharyngitis, upper respiratory infection and headache. Two serious adverse events reported were pyelonephritis and an ear infection. There were a total of 508 ustekinumab injections, and only one injection-site reaction. There were no active tuberculosis cases, anaphylactic reactions, malignancies, opportunistic infections or serum sickness-like reactions through Week 60.

Overall during a year of treatment, ustekinumab was well tolerated by adolescents with responses comparable with those of adults and no unexpected adverse events.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Analgesic Combination in Phase 2 Trials
HTX-011 is in Phase 2 clinical trials. It’s a long-acting formulation of 200 mg bupivacaine or 400 mg bupivacaine with meloxicam given once during surgery for managing post-operative pain.2 Pain intensity scores within the first 24, 48 and 72 hours post surgery were significantly reduced. And the amount of time for the use of the first opioid pain treatment post surgery was increased (48 hours vs. eight hours for placebo-treated patients, P<0.0001). Additionally, 32% of patients received no opioids within 72 hours of their operation, compared with 5% of placebo-treated patients (P<0.0001).

Pages: 1 2 | Single Page

Filed Under: Analgesics, Biologics & Biosimilars, Drug Updates Tagged With: Adolescents, analgesic, Biologics & Biosimilars, Pain, ustekinumab

You Might Also Like:
  • Ustekinumab Found to Be Effective in Adolescents with Psoriasis
  • FDA Approves Ustekinumab for Crohn’s Disease
  • Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis
  • Ustekinumab Has Longer Efficacy Duration than TNFIs for Plaque Psoriasis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)